Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (10531)	2/20/2004 11:49:57 AM
From: scaram(o)uche	Respond to of 52153

Yeah, Bio-Kruncher edited out the last sentence of my email, so I need to make an addendum as well. The last sentence read...... "but please don't post my predictions if they make me look like a flaming, irrational optimist". ;-)

To: Icebrg who wrote (10531)	2/20/2004 2:40:21 PM
From: Icebrg	Read Replies (1) \| Respond to of 52153

Cell Genesys 7:49 pm Cell Genesys confirms publication of GVAX paper (CEGE) 14.28 +1.41: -- Update -- Co confirms that a press release issued yesterday by Baylor University concerned data from the initial Phase 1/2 clinical trial of Cell Genesys' GVAX lung cancer vaccine trial. The data, which were published in the Feb 18, 2004 issue of the Journal of the National Cancer Institute, were previously presented in Dec 2002 at the International Conference on Gene Therapy of Cancer... see 09:04 and 08:13 updates for related commentary. Sometimes it takes time for the markets to take notice. As the above snip notes, this is not really new news although the publishing takes place now. More or less the same data was presented in a PR from CEGE December 16, 2002. Erik cellgenesys.com